Patient Support Programs in Egypt: Build vs. Outsource Guide

If you are a market access, brand, or patient services lead at a pharmaceutical company operating in Egypt, the question of how to structure adherence and patient support is rarely academic. It shows up on the launch plan for a new therapy, in the renewal case for an established brand, and in every conversation where a payer or KOL asks for persistence data you do not yet have a system to produce. The build-vs-outsource decision is one of the first structural choices you make, and it quietly determines your launch timeline, your cost base for the next three to five years, and whether you will have defensible adherence and outcomes data when you need it most.

This guide is written for that decision specifically. It sets aside the generic "what is a patient support program" framing and focuses on the operational and financial trade-offs between running a PSP with an internal team and commissioning a managed program from an established provider in the Egyptian market. Where numbers are given, they reflect what is verifiable and typical, not projections tailored to a single therapy or contract.

What a fully outsourced PSP actually includes

The term "patient support program" covers a wide range of service depth, and this is often where build-vs-outsource conversations go wrong — the two options are compared as if they deliver the same scope, when in practice an outsourced PSP in Egypt is usually a bundled operating model built around six core modules.

• Patient onboarding and enrollment: intake, consent capture, eligibility checks against the program's inclusion criteria, and a documented handover from the prescribing physician or hospital into the program.
• Home injection and infusion support: trained nurses administering or supervising self-injectable or infused therapies at the patient's home, reducing the burden of repeat clinic visits for chronic or biologic regimens.
• Adherence and follow-up: scheduled check-ins, refill reminders, and structured outreach to patients who miss a dose window or a scheduled visit, logged against a defined follow-up cadence.
• Patient and caregiver education: condition-specific counselling on administration technique, storage, and what to do if a dose is missed or a side effect occurs, delivered in a way that a busy outpatient clinic visit rarely allows time for.
• Safety and pharmacovigilance-aligned reporting: a defined pathway for capturing adverse events or product complaints reported by patients during a home visit or follow-up call, and routing them to the sponsoring company's safety team within an agreed timeframe.
• Monthly KPI packs: consolidated reporting on enrollment, visit completion, adherence trends, and drop-off, formatted for a brand or market access team to use directly in internal reviews.

The pharmacovigilance-aligned reporting module deserves a closer look, because it is often assumed rather than specified in a scope-of-work. Operationally, it means the field team is trained to recognise a reportable event during a home visit, the program has a documented escalation path to the sponsor's designated safety contact, and that path is built around the sponsor's own standard operating procedures and the regulatory timelines that apply in Egypt — not a generic template. A managed provider should be able to walk you through exactly how an adverse event moves from a patient's living room to your safety database, and how quickly.

The economics: in-house team vs. outsourced PSP

For a P&L owner, the build-vs-outsource decision is not really about whether a PSP is a good idea — most market access teams agree it is. It is about which structure delivers the required service level at a cost and speed the brand can justify against its lifecycle stage. The comparison below reflects the structural differences that consistently show up between an internally staffed program and a managed PSP run by an established provider.

Each row carries a different weight depending on where the brand sits in its lifecycle. For a pre-launch or newly launched therapy, time to launch and geographic coverage tend to dominate the decision, because slow patient enrollment in month one is difficult to recover from later in the year. For an established brand facing a renewal or budget-impact discussion, reporting quality and the defensibility of the safety workflow usually matter more, because that is the data set the market access team will be asked to defend internally and, at times, externally.

The staffing cost model row is worth dwelling on, because it is where in-house builds most often underperform their original business case. A fixed clinical headcount is a fixed cost whether the program enrolls 50 patients or 500 in its first quarter. An outsourced model that scales with volume converts a chunk of that risk into a variable cost, which is particularly valuable during the unpredictable first six to twelve months of a new therapy's patient support program.

KPIs that matter to market access — and how they're reported

A patient support program that only reports enrollment numbers is not giving a market access team what it actually needs. The KPIs below are the ones that tie directly to decisions a brand or market access lead has to defend, and each should appear in a program's standing reporting rather than being reconstructed manually when a payer or internal stakeholder asks for it.

• 24-hour referral response: the share of patient referrals into the program that receive a first contact within 24 hours. This protects launch momentum — a slow first contact is one of the most common reasons enrolled patients disengage before their first visit.
• Visit documentation rate: the proportion of scheduled home visits with complete clinical documentation. This is the foundation for any adherence or outcomes claim the brand later wants to make, because undocumented visits cannot be counted as evidence.
• Adherence curves: enrollment-to-persistence tracking over time, typically shown month by month. This is the data set most directly useful in HTA and payer conversations, where persistence over 6–12 months is often the metric under scrutiny.
• Drop-off analysis: where in the patient journey enrolled patients disengage — after enrollment, after the first visit, or mid-course — and why, where that reason is captured. This is the data a brand needs for a renewal or budget-impact case, since a program that can explain its drop-off is far more credible than one that can only report a headline adherence percentage.

In Hospitalia-managed PSP programs, medication adherence has run at approximately 85% among enrolled patients — a figure worth citing to internal stakeholders, with the caveat that adherence definitions and measurement windows should always be confirmed against the specific program design before being used in an external document.

Which therapy areas are the best fit for a managed PSP in Egypt?

Not every therapy area benefits equally from a managed PSP, and the fit is worth assessing honestly rather than assuming a one-size-fits-all program design. Diabetes programs, for instance, tend to succeed on the strength of consistent, low-friction adherence touchpoints — reminders, refill tracking, and basic lifestyle counselling delivered often enough to matter, but not so intensively that the cost model breaks down against a large patient population.

Autoimmune and biologic therapies present a different profile. Many require home injection or infusion support delivered by a trained nurse, alongside education on administration technique and storage that a standard outpatient visit rarely has time to cover properly. The clinical bar for the field team is higher here, and program design should reflect that the patient's confidence in self-administration is often what determines whether they stay on therapy past the first few months.

Oncology support programs tend to center less on drug administration and more on symptom management coordination, appointment navigation, and caregiver support — the patient population is frequently in active treatment elsewhere, and the PSP's role is to reduce the gaps between hospital visits rather than to replace clinical care. Rare disease programs sit at the other extreme: enrollment numbers are small, but the depth of case management, the need for direct physician liaison, and the sensitivity of the data collected are all disproportionately high relative to patient count, which makes a generic, high-volume PSP model a poor fit. Cardiovascular therapies often fall in between, combining adherence tracking with periodic monitoring check-ins where early detection of a missed refill or a deteriorating symptom can meaningfully change the outcome trajectory.

The common thread is that therapy area should shape program design, not just program size. A PSP built around a diabetes-style touchpoint cadence will underperform if applied unmodified to a rare disease population, and a heavy, case-management-intensive model built for rare disease will be needlessly expensive if applied to a high-volume, low-complexity therapy.

Regulatory and safety considerations for PSPs in Egypt

In practice, this means a managed PSP's safety workflow is not a fixed, one-size-fits-all process — it is configured against the sponsoring company's existing adverse-event capture procedures, so that a field nurse encountering a reportable event during a home visit follows the same escalation logic the company already uses internally, adapted to a field setting. It also means training the field team specifically on what constitutes a reportable event for the therapy in question, since the threshold and documentation requirements can differ meaningfully between, say, an established oral therapy and a newly launched biologic.

Consent and data handling follow the same principle: the program's intake and consent process should mirror what the sponsor's own compliance function expects, covering what patient data is collected, how it is stored, who at the sponsoring company can access aggregated versus patient-level data, and how long records are retained. These are details worth confirming explicitly in the scope-of-work before launch, rather than assuming they are handled identically across providers.

How a program goes live: timeline from scoping to first patient visit

A managed PSP launch in Egypt generally follows a four-stage sequence. Understanding what happens at each stage helps a market access or brand team plan internal approvals and communications around a realistic timeline, rather than assuming the program can simply switch on once a contract is signed.

1. Scope and design: defining the program's modules, target patient population, geographic coverage, KPI set, and safety escalation pathway against the sponsor's SOPs — this is where the therapy-specific decisions from earlier sections get written into an actual protocol.
2. Build and train: recruiting or assigning the field team, running condition- and product-specific training including administration technique and adverse-event recognition, and configuring the reporting infrastructure that will generate the monthly KPI packs.
3. Launch: opening patient enrollment through the agreed referral pathway, with the first patient visits scheduled against the 24-hour response standard and early enrollment tracked closely for any friction in the referral-to-first-visit handoff.
4. Optimise: reviewing early KPI data — enrollment pace, visit completion, first drop-off signals — and adjusting outreach cadence, staffing allocation, or educational materials before patterns from the first cohort harden into the program's long-term baseline.

The optimise stage is often skipped or rushed in internally built programs, largely because the team that just spent months standing up the infrastructure has limited appetite to revisit its own design within the first quarter. A managed provider running multiple programs concurrently tends to treat this stage as routine, since the same review cadence applies across therapies and can surface issues — a referral source that is not converting, a follow-up call window that is missing patients — before they compound.